Dengue after Zika: characterizing impacts of Zika emergence on endemic dengue transmission

Rebecca K. Borchering^{1*}, Angkana Huang¹, Luis Mier-y-Teran-Romero², Diana P. Rojas³,
Isabel Rodriguez-Barraquer⁴, Leah C. Katzelnick¹, Silvio D. Martinez¹, Gregory D. King¹,
Stephanie C. Cinkovich¹, Justin Lessler², Derek A.T. Cummings^{1*}

¹Department of Biology and Emerging Pathogens Institute, University of Florida, Gainesville, FL, 32610, USA

²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, 21205, USA

³Department of Biostatistics, College of Public Health and Health Professions, University of Florida, Gainesville, FL, 32610, USA

⁴Department of Medicine, University of California, San Francisco, San Francisco, CA, 94143, USA

* Corresponding authors

Abstract:

In 2015 and 2016, Zika virus (ZIKV) swept through many Latin American countries where dengue virus (DENV) is endemic. Dengue and Zika viruses are of the same family, share a vector and may interact competitively or synergistically through human immune responses. We examine dengue incidence data from Brazil and Colombia from before, during, and after the Zika epidemic. We find evidence that dengue incidence was atypically low in 2017 in both Brazil and Colombia. We investigate whether Zika incidence at the state or department level is associated with changes in dengue incidence and find mixed results. We use simulations to investigate expected impact of cross-protection or enhancement between dengue and Zika. Our simulations show that regardless of the mechanism, low periods of dengue incidence are followed by a resurgence in dengue cases. It is therefore likely that countries currently experiencing low levels of dengue incidence will experience large dengue seasons in the near future. By considering multiple combinations of DENV and ZIKV reproduction numbers, we demonstrate that the mixed results of our statistical models are not entirely unexpected. Correlations in DENV and ZIKV reproduction number could contribute to complicating or masking an association between their case counts.

Introduction:

In 2015 and 2016, Zika virus (ZIKV) swept through many Latin American countries¹ where dengue virus (DENV) is endemic. Following this epidemic, many locations appeared to experience abnormally low dengue incidence. DENV and ZIKV share a vector^{2,3} and are both

flaviviruses. Evidence suggests these viruses may interact competitively or synergistically through human immune responses^{4–10}. Changes in surveillance and control in response to Zika^{1,11} could affect reported dengue cases. Conditions (climate¹², vector abundance) that favor Zika may be similar to those favoring dengue. Here, we examine data from Brazil (1999–2017)^{13–15} and Colombia (2007–2017)^{13,16,17} to determine whether dengue incidence has been atypical since the emergence of ZIKV. We demonstrate that dengue incidence was significantly lower than expected in both countries in 2017. Despite these unprecedented low periods, we did not find a negative association between cumulative Zika incidence and biweekly dengue incidence in either country. To gain insight into how immunological interactions would impact the relationship between ZIKV and DENV incidence in this period, we used a stochastic compartmental model of the four DENV serotypes and ZIKV under multiple assumptions. In almost all simulations incorporating strong ZIKV cross-protection against subsequent DENV infection, ZIKV epidemics were followed by a trough in dengue incidence, followed by a larger than average peak in DENV incidence. Correlated hazards of DENV and ZIKV transmission may complicate the relationship between ZIKV incidence and resulting dengue incidence. It is likely that countries experiencing low dengue incidence after the Zika epidemic will experience increases in dengue cases in the near future.

Epidemics of emerging pathogens have the potential to disrupt the ecology of other circulating pathogens. Zika virus (ZIKV) was identified in the Americas in Brazil in late 2015¹⁸, though phylogeographic analyses suggest ZIKV may have arrived as early as mid-2013¹⁹, entering northeast Brazil in early 2014²⁰. The outbreak in the Americas was extensive, affecting 48 countries and territories up through December 2017²¹. Serological evidence has found rates of infection ranging from 56% (Nicaragua²²) to 63% (Salvador, Brazil²³). These are comparable to seroprevalence in previous ZIKV outbreaks; 73% in Yap Island, Micronesia²⁴, 49% in French Polynesia²⁵. Associations between ZIKV infection and severe disease outcomes such as

microcephaly and Guillain-Barré syndrome were recognized by the WHO in March 2016¹, prompting intensified surveillance and control efforts.

Since 2016, Zika incidence in Brazil has dropped precipitously, from over 200,000 probable cases in 2016 to 18,548 in 2017¹³. In Colombia incidence dropped from approximately 90,000 in 2016 to 1,641 in 2017¹³. These reductions are likely the result of widespread immunity throughout affected populations, leaving few individuals susceptible to infection. Multiple human and animal studies show that ZIKV induces potentially neutralizing antibody responses^{26,27}, suggesting enduring ZIKV-specific immunity²⁸.

The primary ZIKV vectors, *Aedes aegypti* and *Aedes albopictus*^{2,3,29}, also transmit chikungunya virus (CHIKV) and dengue virus (DENV). In contrast to CHIKV (an alphavirus), DENV and ZIKV are genetically similar flaviviruses⁸. DENV exists as four antigenically distinct serotypes (DENV1-4). When an individual is infected by DENV, there is a period of cross-protection from infection by other serotypes³⁰. After the period of cross-protection, subsequent infections with different serotypes can result in more severe disease due to antibody dependent enhancement (ADE)^{31,32}. It has been speculated that, due to the similarity between DENV and ZIKV, immunity to one of these viruses may alter the chance of infection or probability of severe disease following exposure to the other virus. Current evidence supports both the potential for enhancement^{4–7} and for cross-protection^{5,7–10}.

Results and discussion

At the population level, the large ZIKV epidemic could plausibly have lead to either increases or decreases in dengue cases. To determine if either was the case, we compared dengue surveillance data from before, during, and after the arrival of ZIKV. We constructed time series of probable case counts for each state in Brazil (1999-2017)^{13–15} and department in Colombia (2007-2017)^{13,16,17}(see Methods, Fig. 1b, 1d, Supplementary Fig. 1). In 2017, Brazil

had the lowest annual incidence rate (IR) of dengue since 2005 (Fig. 1a) and Colombia had the lowest annual dengue incidence since 2007 (the first year of available data) (Fig. 1c).

Departures from expected dengue incidence. We quantified the probability of departures arising by chance from expected dengue incidence using time series models with seasonal variation in autocorrelative effects (see Methods, Supplementary Fig. 2, 3). Biweeks with atypically large incidence occurred significantly more often than expected in Brazil in 2015 (Fig. 2a, 2b). In 2017, Brazil experienced an increase in both atypically high and atypically low biweeks compared to expectation. In Colombia, a significant increase in atypically low biweeks was observed in 2016 and 2017 (Fig. 2c, 2d) (see Methods and Supplementary Fig. 4, 5 for further details).

Hierarchical models characterize departures in expected dengue incidence. To attempt to explain the significant departures that we saw in each location, we built a set of hierarchical time series models that incorporated a number of subnational covariates. These models forecasted dengue incidence using combinations of seasonal dengue terms, year effects, and recent incidence of Zika. For a baseline, we also fit models incorporating chikungunya incidence. CHIKV shares climate and vector determinants as DENV and ZIKV but is of a different viral family and thus is not expected to interact immunologically with flaviviruses.

In models incorporating year effects, we found that biweekly expected dengue incidence in 2015 was higher than that of corresponding biweeks in other years in both Brazil (mean: 2.21-fold increase, 95% CrI: 1.45 to 3.37) and Colombia (mean: 1.11-fold increase, 95% CrI: 0.96 to 1.29). In contrast, we found that biweekly dengue incidence in 2017 was lower in both Brazil (relative incidence mean: 0.63, 95% CrI: 0.46 to 0.86) and Colombia (relative incidence mean: 0.23, 95% CrI: 0.18 to 0.29). At the subnational-level there are differences in the significance

and direction of these effects (Fig. 3b, 3d), with the exception of 2017 in Colombia, where there is a significant reduction in biweekly dengue incidence in all departments (Fig. 3d).

We found a positive association between the previous biweek's Zika incidence and dengue transmission potential in Brazil (mean coefficient: 0.16, 95% CrI: 0.05 to 0.26, Fig. 3a). Putting this coefficient in context, 1000 Zika cases observed in the previous biweek translates to a multiplicative increase of about 3 times as many expected dengue cases in the following biweek (mean: 2.92, 95% CrI: 1.40 to 6.15). We also found a positive association between cumulative Zika incidence on dengue transmission potential in Brazil (mean coefficient: 0.04, 95% CrI: 0.003, 0.08). No significant association were found between Zika incidence and dengue transmission potential in Colombia.

In Brazil, cumulative (mean coefficient: 0.04, 95% CrI: 0.01 to 0.08, Fig. 3a) and biweekly (mean coefficient: 0.11, 95% CrI: 0.04 to 0.17, Fig. 3a) chikungunya incidence were positively associated with expected dengue transmission in the following biweek (Fig. 3a, 3c, Supplementary Fig. 6). No significant association were found between chikungunya incidence and dengue transmission potential in Colombia.

In Brazil, states with positive effects of Zika on dengue transmission potential often observed positive effects of chikungunya on dengue (Supplementary Fig. 6). Totals of suspected Zika and suspected chikungunya cases at state- and department-level were positively correlated (Supplementary Fig. 7), consistent with potentially shared environmental suitability conditions for transmission of these viruses.

We tested whether the direction of country-level effects was an artifact of our model implementation, by replacing 2015 to 2017 with a random three consecutive years of data preceding 2015 and then repeating the model fitting procedure. We did not find agreement in the directionality of the country-level effects across the resulting models (see Supplementary Fig. 8), supporting our main results.

In 2017, low dengue incidence rates (Fig. 1), atypically high numbers of biweeks with lower than expected dengue incidence (Fig. 2), and negative country-level effects (Fig. 3a and 3c) indicate a reduction in dengue incidence in Brazil and Colombia. Utilizing available Zika case data, we were unable to establish a direct link between this reduction and the Zika epidemic. It is important to note that there are limitations to using passive surveillance data (as we have done here), particularly when novel pathogens are involved. In the case of ZIKV invasion in the Americas, many cases that occurred early in the epidemic were not reported, since it took time to first identify the presence of ZIKV and then to establish reporting protocols. The unavailability of Zika case count data during the height of the ZIKV epidemic in northeast Brazil, one of the most severely affected regions³³, may have contributed to our inability to identify a relationship between cumulative Zika cases and observed dengue incidence. In both Brazil and Colombia, misclassified cases (potentially resulting from shared symptoms between case definitions of dengue, Zika, and chikungunya) also may have restricted our ability to detect such a relationship. Other factors such as climatological effects¹² or additional mosquito control efforts^{1,11} and avoidance behavior may have played a role in reducing dengue incidence.

Stochastic simulations incorporating immune-mediated interactions. We tested whether immune-mediated interactions between DENV and ZIKV could produce the dengue dynamics observed in Brazil and Colombia by simulating the arrival of Zika in a dengue endemic population (Fig. 4). We used a stochastic compartmental model that incorporated combinations of cross-protection or enhancement between the two viruses. In simulations where ZIKV infection temporarily reduces an individual's risk of DENV infection, Zika epidemics are followed by a trough in dengue incidence ranging from 2.2 years to 3.4 years depending on the scenario (Fig. 4). Multiple simulations showed increases in dengue after troughs ranging from a 1.2-fold increase to a 2.5-fold increase (Fig. 4). Based on our simulations, which assumed that cross-protection lasts one year on average, the time until dengue resurgence (trough duration) would

likely be longer than the assumed one-year duration of cross-protection. In all scenarios, suppression of DENV transmission resulted in subsequent increases in DENV prevalence, suggesting that the low period of incidence observed in 2017 may be followed by large increases in DENV.

We also tested the impact of correlation in ZIKV and DENV transmission intensity on observed associations between cumulative ZIKV and DENV incidence (see Supplementary Fig. 9). We consistently observed a reduced impact of ZIKV on dengue in simulations where DENV transmissibility was assumed to be higher. When the transmissibility of ZIKV and DENV were assumed to be equal, reductions in DENV due to cross protection were not larger in simulations with higher ZIKV attack rates as the impact of ZIKV was offset by increased DENV transmissibility. These results are consistent with an unclear or variable relationship between DENV reductions and cumulative ZIKV incidence as we have observed in the data.

Our results demonstrate a significant decline in dengue cases in 2017 in Brazil and Colombia. Studies involving laboratory confirmed cases and enhanced serosurveillance (see for example Ribeiro et al. 2018³³) will play an important role in pinpointing the mechanism underlying this reduction. Our simulation results show that troughs in dengue incidence are followed by atypically high dengue levels. Atypically low dengue case counts observed recently in Brazil and Colombia suggest that population-level susceptibility to symptomatic dengue has been building. Such high levels of susceptibility could fuel large dengue epidemics in upcoming seasons.

Figure 1: Estimated dengue incidence in Brazil and Colombia (per 100,000). States are arranged by region and then by latitude from North to South. Note that Zika incidence was not systematically reported prior to 2016 in Brazil (a) or late 2015 in Colombia (c) and that Chikungunya was not systematically reported prior to 2015 and late 2014 respectively in Brazil (a) and Colombia (c). In Brazil, updated data from the following year's bulletin for 2014 to Epiweek 42, 2017 is used.

Figure 2: Comparison between predicted and observed dengue incidence. Results for 2014-2017 are shown for Brazil (a, b) and Colombia (c, d) (see Supplementary Fig. 4, 5 for full time series). **b, d** Red or blue indicate that the observed incidence fell above or below the median of 500 draws from the posterior of predicted values for that biweek. Medium or dark shading indicates that the observed incidence fell outside of the 90% or 95% prediction interval (PI) for that biweek. **a, c** The number of biweeks with observations falling below (blue) or above (red) the 90% PI are displayed with a quantile of the observed number of significant biweeks out of a distribution generated by 10,000 bootstrapped replicates. In these replicates, year labels were randomly re-assigned for each location before counting the biweeks in each year that were above or below the 90% PI (see Methods for further details).

Figure 3: Spatial hierarchical biweekly dengue incidence models. Shared coefficients from the year model are highlighted in yellow. Mean and 95% credible intervals (CrI) for the shared effect coefficients for Brazil (a) and Colombia (c). Zika and chikungunya coefficients are estimated from autoregressive dengue models. Positive (negative) coefficients indicate increases (decreases) in expected dengue incidence for the year model and indirectly as effects on transmission for the Zika and chikungunya models. Mean and 95% CrI for the year multiplier on expected dengue incidence for Brazil (b) and Colombia (d). Shared multipliers in the top row of panels b and d are translated from coefficients in panels a and c. Other rows display subnational effects (combined shared and location specific effects).

Figure 4: Simulation results incorporating immune-mediated interactions between DENV and ZIKV. Mean and 95% inter-quantile range from stochastic simulations spanning 10 years post ZIKV-introduction. 100 simulations per scenario. ZIKV introduced after a 100 year burn-in period for four DENV serotypes. **a-d** Individuals with previous dengue exposure experience 20% of the DENV force of infection (FOI) that a fully susceptible person would. **e-h** Individuals with previous ZIKV exposure experience 80% of the FOI that a fully susceptible person would. **i-l** Individuals with ZIKV exposure experience 20% of the DENV FOI (same amount of cross-protection between dengue and Zika than between dengue serotypes).

Methods

Data sources. We collated data from Brazil (27 states) and Colombia (32 departments) into a public data repository¹³. For Brazil, monthly dengue data is available for some states starting in 1986 from the National Health Foundation-FUNASA and for all 27 states starting in 1999. We used monthly data from 1999 to 2012. Monthly data for 2001-2012 were taken from the centralized System for Reporting of Notifiable Conditions (SINAN)¹⁴. For 2013-2017, we entered weekly data found in the Epidemiological Bulletins¹⁵ published by the Secretariat of Health Surveillance in the Ministry of Health, Brazil where the number of probable cases, severe dengue, dengue with alarm symptoms, and dengue deaths were reported. Severe dengue and dengue with alarm symptoms cases are clinically diagnosed based on symptoms. Case definitions have changed over time, but we use probable case counts (including both confirmed and unconfirmed cases) in all of our analyses. Zika and chikungunya case counts were first reported in the Epidemiological bulletins for Epidemiological week (Epiweek) 13, 2016 and Epiweek 9, 2016 respectively.

Data entry accuracy was checked by re-entering 10% of the weekly bulletins. Within these bulletins, we found that less than 0.01% of the numeric fields entered were inconsistent between the primary and secondary entries.

The Epidemiological Bulletins published in Brazil for 2014-2017 also report the corresponding dengue data for the previous year. We use the available previous year data reported in the 2014-2018 bulletins to obtain probable dengue case counts for 2013-2017 Epiweek 42 since these data are most comparable to the preceding historical data. Analogous updated probable Zika and chikungunya case counts were first reported in 2017 and 2016 respectively. We use these updated counts in our analyses. We also use data on the cumulative number of microcephaly cases and other central nervous system disorders in newborns³⁴ reported in Brazil since Epiweek 45, 2015 through the end of 2016. Cumulative number of cases

later disregarded from the system was also reported. We therefore deduct the disregarded counts from the case counts.

For Colombia, we use weekly department-level probable dengue case count data from the Colombian Instituto Nacional de Salud (INS) website¹⁶. This dataset includes weekly dengue case counts for 2007-2017, with severe dengue cases reported separately for 2014-2017. We excluded cases with an unknown department and those that were considered imported from other countries. When combined counts for districts with the counts for the department in which they are located, whenever they were reported separately. We extracted additional data for probable Zika and chikungunya cases from the weekly Epidemiological Bulletins¹⁷ for 2015-2017. According to the Epidemiological Bulletins published by Colombia's Directorate of Surveillance and Risk Analysis in Public Health, Zika has been in the country since 2015 Epiweek 40 with the number of cases first reported in the 2016 Epiweek 1 bulletin. In the updated Colombia dataset, the first documented Zika cases were in 2015 Epiweek 25. Case counts in the bulletins of both countries were given as cumulative counts.

We also gathered subnational level population size data for both Brazil and Colombia¹³ from the Instituto Brasileiro de Geografia e Estatística³⁵ and Departamento Administrativo Nacional de Estadística Colombia³⁶ respectively.

Incidence time-series construction. We construct biweekly time series for probable dengue, Zika, and chikungunya case counts for each state in Brazil and department in Colombia. The Epidemiological Bulletins provide estimates for the cumulative number of cases since Epiweek 1 reported up until the corresponding Epiweek. These cumulative counts are not fixed and are updated as new information becomes available, such as updated knowledge of clinical symptoms or related test results. When the diagnosis of a case is changed to another disease or when samples are negative for the originally designated pathogen, these cases are removed

from the cumulative counts. Thus, the published cumulative counts sometimes decrease in consecutive bulletins.

To avoid negative biweekly incidence values, we constructed strictly nondecreasing upper, middle, and lower approximations of the cumulative time series. Working backward from the most recent time point, we accounted for decreases in the cumulative count by either subtracting the difference from all previous time points (lower approximation) or by setting the higher incidence equal to the lower incidence in the following biweek (upper approximation). This process was repeated for all time points, resulting in a strictly nondecreasing time series. The middle approximation is constructed by averaging the values of the upper and lower approximation at each time point.

To determine which approximation to use in our analyses, we calculated the sum of squared errors for each of the approximations using the updated previous year data (2014-2016) reported in the 2015-2017 Epidemiological Bulletins from Brazil. We found that the middle approximation best represented our target time series; this approximation was thus used for the construction of all case count time series for both Brazil and Colombia. For Brazil, we use the final (updated previous year) data to construct our time series, when it is available. When performing our analysis, we used updated data for Brazil up through Epiweek 42, 2017 (since updated data for the rest of 2017 was unavailable).

For each location and disease, we fit a spline to the adjusted cumulative incidence curve by using the `smooth.spline` function from the `stats` package in R. A knot was assigned to each data point. We used a binning procedure to translate the continuous spline into a biweekly sequence of predicted case counts. Cases were assigned to biweeks with probabilities based on the difference in predicted case counts at endpoints of consecutive biweeks. When consecutive predicted spline values decreased, the probability of assigning cases to the first biweek was set to zero. We repeated the reassignment process 1000 times to create 1000 case count time-series and then calculated the mean incidence for each biweek (averaged over the

1000 simulations), rounded down to the nearest integer to obtain the final biweekly case count.

In what follows, we refer to this value as the “observed incidence”.

Seasonality evaluation. For each dengue season, we identified the biweeks with the three greatest numbers of cases in each subnational location (states in Brazil and departments in Colombia). In Brazil, dengue seasons were defined to range from biweek 18 to biweek 17 of the next year, to avoid splitting the season into multiple years. In Colombia, there was not a clear start and end of a dengue season, so we did not define a particular season that spans across multiple calendar years. See Supplementary Fig. 1 which describes the seasonality for states and regions.

Time series models. For each year of available data, we fit a one-step autoregressive model with negative binomial errors for each state in Brazil and each department in Colombia using incidence data from that location in all other years. For each the location, the number of dengue cases in the following biweek is modeled as follows:

$$C_{j,t+1} \sim NB(\lambda_{j,t}, \theta)$$

$$\log \lambda_{j,t} = \beta_0 + \beta_j \log(C_{j,t} + 1) + \log N_t$$

where β_0 is an intercept, β_j is a multiplicative factor scaling transmission for biweek t in biweek category $j \in \{1, \dots, 26\}$, $C_{j,t}$ is the number of probable dengue cases in biweek t , N_t is the population size (specific to the year and location), and θ is the dispersion parameter. We did not fit a separate model for Vaupés, Colombia, since there are no probable dengue case counts reported for this department in 2007, 2008, 2009, 2011, and 2015. We also did not fit any regression models for the capital of Colombia, Bogotá, since there is limited corresponding dengue incidence and these cases are considered to originate from other departments.

Fitting procedure and model performance. We fit all time series models using the rstanarm R package³⁷ by implementing Bayesian MCMC methods. For each model, we sampled four chains with 10,000 iterations each (5,000 iterations included as warmup) for subnational level models and 10,000 iterations each for national models. Convergence was evaluated by using the launch_shinystan function of the rstanarm R package³⁷. We primarily assessed the convergence of our models using the Gelman-Rubin convergence statistic³⁸ and deemed convergence adequate when $\hat{R}$ is less than 1.1. We also checked to see whether there were any parameters with an effective sample size less than 10% of the total sample size or any parameters with a Monte Carlo standard error greater than 10% of the posterior standard deviation. We noted whether there were any divergent transitions after the warmup period. We evaluated model performance by calculating R^2 values for the focal year of predictions (out-of-sample values) and predictions of the data used to fit the models (in-sample values) (see Supplementary Fig. 3).

Comparisons between predicted and observed dengue incidence. Starting with the second biweek of data for a given location, we sampled 500 values from the posterior distribution for predicted incidence for the corresponding model (fit using data from all other years). We then evaluated the quantile of the observed incidence in that biweek in the cumulative distribution of posterior predicted values. We consider the observed state- or department-level incidence in a particular biweek to be statistically atypical if it falls outside of the 90% prediction interval (PI), i.e. if the observed quantile is less than 0.05 or greater than 0.95 (see Fig. 2 and Supplementary Fig. 4). We repeated this analysis using a Bonferroni adjusted quantile (Supplementary Fig. 5).

Further, we implemented a permutation test to consider whether the number of atypically high or low observed incidence values in each year (separately for each country) was significant. For each location, we reassigned the years (sampling without replacement). Then for each year we counted the number of statistically high or low values of observed incidence. We

repeated this procedure 10,000 times and then found the quantile of the observed numbers of atypically high or low biweeks within the cumulative distribution function generated from the permuted data (see Fig. 2a and 2c). This permutation procedure preserves temporal correlation within the years. We considered a second permutation test that preserved spatial correlation within each biweek. For this test, we reassigned biweek labels. For each biweek, we sampled without replacement from the years of available predictions for the corresponding biweek category (ranging from 1-26). We then reassigned the quantiles of that particular biweek to be the corresponding incidence from that biweek category in the resampled year. Again, we performed 10,000 permutations and found the quantile of the observed counts of statistically high or low biweeks in the corresponding cumulative distribution function. Results were similar between the two permutation tests. Between the two tests, quantile differences for each year were less than 5% (median value 0.012, $n=58$) and significant results ($q>95\%$) presented in Figure 2 were maintained. Note that we did not include 1999 in the permutation test for Brazil since data is not available for the entire year in Acre (the first dengue case in the dataset is in August 1999).

Hierarchical regression models. Separately for Brazil and Colombia, we fit a set of spatial hierarchical models for dengue incidence (using state-level data for Brazil models and department-level data for Colombia models) with negative binomial errors. We considered models with either a log-additive effect for recent years (2015, 2016, 2017) or a multiplicative effect of either Zika or chikungunya case counts (previous biweek or total count recorded up to and including the previous biweek) on expected dengue cases. We focus on an absolute incidence version of the year effect model, where a dengue seasonality (biweek) indicator is used instead of the log-dengue case count predictor used in the other models. The subnational location-specific effects account for deviation from the country-level shared effects. During the

fitting procedure, a variance term is also fit for the distribution of location-specific effects. These models take the following form:

$$C_{i,j,t+1} \sim NB(\lambda_{i,j,t}, \theta)$$

Additive model:

$$\log \lambda_{i,j,t} = \beta_0 + \beta_{i,j} + \alpha_{\text{year}(t)} + \alpha_{i,\text{year}(t)} + \log N_{i,t}$$

$$\alpha_{i,\text{year}} \sim N(0, \sigma_{\text{year}})$$

Multiplicative model:

$$\log \lambda_{i,j,t} = \beta_0 + \beta_{i,j} \log(C_{i,j,t} + 1) + (\alpha + \alpha_i) \log(X_{i,t} + 1) + \log N_{i,t}$$

$$\alpha_i \sim N(0, \phi)$$

In the additive model, α_{year} represents the shared effect for 2015, 2016, and 2017. $\alpha_{i,\text{year}}$ and α_i are location-specific (subnational) terms for the additive year effect and multiplicative arbovirus-related incidence effect respectively (with dispersion parameters σ_{year} and ϕ). There is one intercept coefficient (β_0) and one coefficient for each state biweek pair ($\beta_{i,j}$), where i ranges over the subnational locations and j ranges over the 26 biweeks. Additionally, there is an offset for year-specific subnational population size ($N_{i,t}$). $X_{i,t}$ represents either: Zika or chikungunya incidence (either at biweek t or the cumulative total number of cases reported up through biweek t in location i). We consider year and arbovirus-related incidence coefficients to be significant when their 95% Bayesian credible interval (CrI) does not overlap zero.

Stochastic compartmental model. We developed a four serotype DENV model that also allowed for ZIKV infection in both mosquito and human populations. There are six mosquito compartments: susceptible, infected with one of the four dengue serotypes, and infected with ZIKV. The human compartments are based on both DENV and ZIKV status. With respect to DENV infection status, individuals in the human population are either susceptible, infectious, cross-protected, or recovered. We keep track of primary and secondary DENV infections and

assume that after two heterotypic DENV infections, individuals become immune to further DENV infections. Homotypic reinfections are not allowed in the model. The human classes are further stratified depending on the individual's ZIKV status: either susceptible, infectious, cross-protected (from DENV), or recovered. There are 125 total compartments in the model.

We considered a suite of immune-mediated interaction scenarios, considering the possibility of enhancement or cross-protection. The enhancement scenarios we considered included: no enhancement, DENV enhances DENV, DENV enhances DENV and ZIKV, and enhancement in all directions. We incorporated a symmetric cross-protective effect, i.e. for a period of time, a dengue infection would reduce the hazard of a future Zika infection and a Zika infection would reduce the hazard of a future dengue infection. Cross-serotype dengue protection (80% hazard reduction to other DENV serotypes) was included in all scenarios. The average duration of cross-protection between dengue serotypes was one year ($\gamma = 1$). We considered the case when cross-protection between dengue and Zika also lasted one year on average. The scenarios without cross-protection did allow for a reduced hazard for approximately 4 days ($\gamma = 1/100$). We considered two levels of cross-protection between DENV and ZIKV. The high-level matched the level of cross-serotype dengue protection ($\rho = 0.2$). The low-level of cross-protection reduced the hazard for the other virus by only 20% ($\rho = 0.8$).

We ran 100 simulations for each scenario using a tau-leap approximation of the Gillespie method in Fortran. ZIKV was introduced into the mosquito population after 100 years of DENV only simulations with randomized initial conditions. An additional 20 years of data was simulated after the introduction of ZIKV. We considered DENV and ZIKV reproduction numbers for all combinations of 2 and 4, and for the case when both are set to 3 (see Supplementary Fig. 9). The human population size was 10 million and the mosquito population size was 20 million. Simulation data analysis was performed in MATLAB and R.

To evaluate the effects of incorporating cross-protection or enhancement, we consider changes in trough duration and peak size. All scenarios that incorporated an immune-mediated

interaction were evaluated against the baseline determined by the scenario with no enhancement and no cross-protection between DENV and ZIKV. We define the trough duration to be the length of time that aggregated DENV prevalence is consecutively less than on half of the average incidence following the introduction of ZIKV, in the baseline scenario (approximately 16 individuals per 100,000 population). We set the trough duration to zero for all simulations that did not include a complete trough within the 20 years following the introduction of ZIKV. Peak size is defined to be the maximum dengue prevalence value, aggregated across all serotypes, in the 20 years following the introduction of ZIKV. Changes in peak size resulting from incorporating an immune-mediated interaction were evaluated by dividing the average peak size by the average peak size in the baseline case (where the average is taken across the 100 simulations of each scenario).

Legends for Supplementary Figures:

SI Figure 1: Dengue seasonality by biweeks with the top three highest incidence values for each season. Seasons are defined to range from biweek 18 to biweek 17 of the following year (biweek 26 is represented as biweek 0 below). Frequencies of peak biweek are displayed for each state in Brazil **(a)** and department in Colombia **(b)**. Black lines show the average frequency for each biweek across locations within each region.

SI Figure 2: Variation in the stan model coefficients for each biweek. Results are shown for coefficients aggregated at the region **(a, c)** and state (Brazil in **b**) or department (Colombia in **d**) level.

SI Figure 3: Bayesian R-squared plots for subnational location specific stan model predictions versus observed incidence for Brazil **(a)** and Colombia **(b)**. The gray line corresponds the R-

squared value for all of the biweeks that were included in the model fitting. The black dots show the Bayesian R-squared value for the year when it was left out of the model fitting. The x-axis indicates the year that was left out, and ranges over all years in the dataset 1999-2017 in Brazil and 2000-2017 in Colombia.

SI Figure 4: Comparison between predicted and observed incidence. Red and blue indicate that the observed incidence was above and below the median value of the posterior distribution of predicted values for that biweek, respectively. Dark biweeks indicate that the observed incidence was outside of the 95% prediction interval and medium shaded biweeks indicate that the observed incidence was outside of the 90% prediction interval. Results are shown for Brazil (a) and Colombia (b).

SI Figure 5: Bonferroni adjusted quantile plot for full time series and recent years. Quantile values are based on the location of the observed incidence in the cumulative distribution of 500 sampled posterior prediction values. Results are shown for Brazil (a) and Colombia (b).

SI Figure 6: Dengue time series model results with spatial hierarchical structure and arboviral disease covariates. Mean and 95% Bayesian credible intervals are displayed for the shared effect (top row) and for the location specific effects (other rows ordered by region and then latitude) for Brazil (a-d) and Colombia (e-h). Location specific effects are displayed as the sum of shared coefficient and location specific coefficient. Models are displayed for biweekly Zika cases (b, f), biweekly chikungunya cases (d, h), cumulative Zika cases (a, e), and cumulative chikungunya cases (c, g).

SI Figure 7: Correlation between arbovirus related case count totals for states in Brazil (**a, b, d, e**) and departments in Colombia (**c**). Correlation coefficients are displayed in the bottom right corner of each panel.

SI Figure 8: Hierarchical model shared effects for permuted recent year datasets. Mean and 95% Bayesian credible intervals are displayed for shared effect coefficients from models fit using the actual dataset (leftmost panels) and alternative datasets where 2015 to 2017 were replaced with three consecutive years of data preceding 2015 for Brazil and Colombia. Nonsignificant results are displayed with light shading.

SI Figure 9: Effects of immune-mediated interactions between DENV and ZIKV on case counts in stochastic simulations. For each combination of cross-protection, enhancement, and R_0 pair, the average ratio (over 100 simulations) between cumulative DENV cases over 1 year (**a**) and 2 years (**b**) after the introduction of ZIKV is plotted against the ratio of cumulative ZIKV cases with and without immune-mediated interactions with DENV. Values above 1 indicate increases in counts and values below 1 indicated decreases compared to the average value from the corresponding scenario without enhancement or ZIKV cross-protection against DENV. For each enhancement and cross-protection scenario pair, linear model fits to the averages (over the 5 R_0 pairs considered) are displayed as gray lines. Negative slopes are consistent with the hypothesis that higher ZIKV incidence is associated with lower DENV incidence. For the case when DENV $R_0 = 2$ and ZIKV $R_0 = 2$, panel **c** shows the relative changes in cumulative DENV incidence over 2 years post-ZIKV introduction (blue points) and changes in DENV peak size (red points). Black vertical lines separate the enhancement scenarios and the level of cross-protection increases from left to right within these sections. Relative changes in peak size are based on the highest DENV incidence in 20 years post-ZIKV introduction versus 20 years pre-ZIKV.

References:

1. WHO. Situation Report-Zika virus, microcephaly and Guillain-Barré syndrome (28 July 2016). Available at <http://origin.searo.who.int/entity/bhutan/who-zika-28-7-16.pdf> (accessed on: November 9, 2018). (2016).
2. Ayres, C. F. J. Identification of Zika virus vectors and implications for control. *Lancet Infect. Dis.* **16**, 278–279 (2016).
3. Chouin-Carneiro, T. & dos Santos, F. B. Transmission of Major Arboviruses in Brazil: The Role of *Aedes aegypti* and *Aedes albopictus* Vectors. in *Biological Control of Pest and Vector Insects* (ed. Shields, V. D. C.) (InTech, 2017).
4. Bardina, S. V. *et al.* Enhancement of Zika virus pathogenesis by preexisting antinflavivirus immunity. *Science* **356**, 175–180 (2017).
5. Dejnirattisai, W. *et al.* Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. *Nat. Immunol.* **17**, 1102–1108 (2016).
6. Paul, L. M. *et al.* Dengue virus antibodies enhance Zika virus infection. *Clin Transl Immunology* **5**, e117 (2016).
7. Stettler, K. *et al.* Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. *Science* **353**, 823–826 (2016).
8. Barba-Spaeth, G. *et al.* Structural basis of potent Zika–dengue virus antibody cross-neutralization. *Nature* **536**, 48 (2016).
9. Swanstrom, J. A. *et al.* Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus. *MBio* **7**, (2016).
10. Rodriguez-Barraquer, I. *et al.* Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. *Science* **363**, 607–610 (2019).
11. da Silva Augusto, L. G. *et al.* *Aedes aegypti* control in Brazil. *Lancet* **387**, 1052–1053 (2016).

12. Caminade, C. *et al.* Global risk model for vector-borne transmission of Zika virus reveals the role of El Niño 2015. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 119–124 (2017).
13. Huang, A., Borchering, R. K., Rojas, D. P., & Cummings, D. A. T. UF-IDD/dengue-Zika-chik_Americas: February X, 2019. (2019). Zenodo DOI: X.
14. Ministerio da Saude Brasil. Sistema de de Informação de Agravos de Notificação, Sinan Net. Available at <http://tabnet.datasus.gov.br/cgi/deftohtm.exe?sinanwin/cnv/denguebr.def> (accessed on: November 3, 2017).
15. Ministerio da Saude Brasil. Monitoramento dos casos de dengue, febre de chikungunya e febre pelo vírus Zika até a Semana Epidemiológica 52, 2015. *Boletim Epidemiológico* Available at: <http://portalms.saude.gov.br/boletins-epidemiologicos#> (accessed on: November 9, 2018).
16. Instituto Nacional de Salud Colombia. Vigilancia Rutinara Historica 2007-2017. *Portal Web SIVIGILA 2018/2020* Available at: http://portalsivigila.ins.gov.co/sivigila/documentos/Docs_1.php (accessed on: December 24, 2018).
17. Instituto Nacional de Salud Colombia. Boletín Epidemiológico. Available at: <https://www.ins.gov.co/buscador-eventos/BoletinEpidemiologico/Forms/AllItems.aspx>.
18. Campos, G. S., Bandeira, A. C. & Sardi, S. I. Zika Virus Outbreak, Bahia, Brazil. *Emerg. Infect. Dis.* **21**, 1885–1886 (2015).
19. Lednicky, J. *et al.* Zika Virus Outbreak in Haiti in 2014: Molecular and Clinical Data. *PLoS Negl. Trop. Dis.* **10**, e0004687 (2016).
20. Faria, N. R. *et al.* Establishment and cryptic transmission of Zika virus in Brazil and the Americas. *Nature* **546**, 406–410 (2017).
21. WHO. Situation Report-Zika virus, microcephaly, Guillain-Barré syndrome (10 March 2017) Available at <http://apps.who.int/iris/bitstream/10665/254714/1/zikasitrep10Mar17-eng.pdf?ua=1> (accessed on November 9, 2018). (2017).

22. Zambrana, J. V. *et al.* Seroprevalence, risk factor, and spatial analyses of Zika virus infection after the 2016 epidemic in Managua, Nicaragua. *Proc. Natl. Acad. Sci. U. S. A.* **115**, 9294–9299 (2018).
23. Netto, E. M. *et al.* High Zika Virus Seroprevalence in Salvador, Northeastern Brazil Limits the Potential for Further Outbreaks. *MBio* **8**, (2017).
24. Duffy, M. R. *et al.* Zika virus outbreak on Yap Island, Federated States of Micronesia. *N. Engl. J. Med.* **360**, 2536–2543 (2009).
25. Aubry, M. *et al.* Zika Virus Seroprevalence, French Polynesia, 2014–2015. *Emerg. Infect. Dis.* **23**, 669–672 (2017).
26. Robbiani, D. F. *et al.* Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. *Cell* **169**, 597–609.e11 (2017).
27. Sapparapu, G. *et al.* Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. *Nature* **540**, 443–447 (2016).
28. Montoya, M. *et al.* Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas. *J. Infect. Dis.* **218**, 536–545 (2018).
29. Vega-Rúa, A., Zouache, K., Girod, R. & Failloux, A. B. High vector competence of *Aedes aegypti* and *Aedes albopictus* from ten American countries as a crucial factor of the spread of Chikungunya. *Journal of* (2014).
30. Sabin, A. B. Research on dengue during World War II. *Am. J. Trop. Med. Hyg.* **1**, 30–50 (1952).
31. Screaton, G., Mongkolsapaya, J., Yacoub, S. & Roberts, C. New insights into the immunopathology and control of dengue virus infection. *Nat. Rev. Immunol.* **15**, 745–759 (2015).
32. Halstead, S. B. Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. *Microbiol Spectr* **2**, (2014).

33. Ribeiro, G. S. *et al.* Does immunity after Zika virus infection cross-protect against dengue? *Lancet Glob Health* **6**, e140–e141 (2018).
34. Ministerio da Saude Brasil. Informe epidemiológico 47-Semana Epidemiológica (SE) 40/2016 (02/10/2016 a 08/10/2016): monitoramento dos casos de microcefalia no Brasil. (2016).
Available at: <http://portalms.saude.gov.br/saude-de-a-z/microcefalia/informes-epidemiologicos> (Accessed: October 17, 2017).
35. Instituto Brasileiro de Geografia e Estatística. *Estimativas de População*. Available at: <https://sidra.ibge.gov.br/tabela/6579> (Accessed: 21st December 2018)
36. Departamento Administrativo Nacional de Estadística. *Estimaciones de población 1985-2005 y proyecciones de población 2005-2020 total departmental por área*. Available at: https://www.dane.gov.co/files/investigaciones/poblacion/proyepobla06_20/Municipal_area_1985-2020.xls. (Accessed: 25th October 2017)
37. Gabry, J. & Goodrich, B. rstanarm: Bayesian applied regression modeling via Stan. *R package version 2*, (2016).
38. Gelman, A. & Rubin, D. B. Inference from Iterative Simulation Using Multiple Sequences. *Stat. Sci.* **7**, 457–472 (1992).
39. Rasmussen, S. A., Jamieson, D. J., Honein, M. A. & Petersen, L. R. Zika virus and birth defects—reviewing the evidence for causality. *N. Engl. J. Med.* **374**, 1981–1987 (2016).

Supplementary Information is available in the online version of the paper.

Acknowledgements We thank S.E. Bellan, M.A. Johansson, and members of the U.F. and J.H.U. Infectious Disease Dynamics groups for helpful discussions. This research was supported by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (grant R01AI102939).

Author Contributions: R.K.B, A.H, S.D.M. and G.D.K. synthesized the data; R.K.B., A.H., S.M and S.S.C. analyzed the data; R.K.B. fit the statistical models with assistance from J.L. and D.A.T.C; L.M.-T.-R. performed the simulations, L.M.-T.-R. and R.K.B. analyzed the simulation results; R.K.B., A.H., D.P.R, I.R.-B., L.M.-T.-R., J.L. and D.A.T.C interpreted the results; R.K.B., A.H. and D.A.T.C. wrote the original draft; L.K., D.P.R, I.R.-B., L.M.-T.-R., J.L. and D.A.T.C. contributed written feedback. All authors wrote the manuscript.

Author Information: The authors declare no competing interests. Correspondence should be addressed to either R.K.B. (rborcheri@ufl.edu) or D.A.T.C. (datc@ufl.edu).

Data Availability Statement: The case count and population data gathered and analyzed in this study are available in GitHub repository UF-IDD/dengue-Zika-chik_Americas (DOI 10.5281/zenodo.2566509). Simulation data is available upon reasonable request.

Code Availability Statement: The code used to process the case count data is available in GitHub repository UF-IDD/dengue-Zika-chik_Americas (DOI 10.5281/zenodo.2566509). Simulation code is available upon reasonable request.